Inhibitors of fatty acid amide hydrolase reduce carrageenan-induced hind paw inflammation in pentobarbital-treated mice: Comparison with indomethacin and possible involvement of cannabinoid receptors

British Journal of Pharmacology

Volumn 146, Issue 3, 2005, Pages 467-476

  Holt, Sandra ^a   Comelli, Francesca ^b   Costa, Barbara ^b   Fowler, Christopher J ^a  

^a UMEÅ UNIVERSITY   (Sweden)

^b UNIVERSITY OF MILANO BICOCCA   (Italy)

Author keywords

Carrageenan; Endocannabinoid; Fatty acid amide hydrolase; Indomethacin; Inflammation; SR144528; URB597

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 4,4' ISOPROPYLIDENEDIPHENOL; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ANTIINFLAMMATORY AGENT; CANNABINOID 1 RECEPTOR; CANNABINOID 2 RECEPTOR; CANNABINOID RECEPTOR; CANNABINOID RECEPTOR ANTAGONIST; CAPSAZEPINE; CARRAGEENAN; CYCLOHEXYLCARBAMIC ACID 3' CARBAMOYLBIPHENYL 3 YL ESTER; FATTY ACID AMIDASE; INDOMETACIN; ISOPROTEIN; PENTOBARBITAL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RIMONABANT; UNCLASSIFIED DRUG;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; ENCEPHALITIS; ENZYME ACTIVITY; ENZYME INHIBITION; EX VIVO STUDY; HINDLIMB; IN VIVO STUDY; INFLAMMATION; LIMB DISEASE; MALE; MOUSE; MYELITIS; NONHUMAN; PAW EDEMA; PRIORITY JOURNAL; PROTEIN FUNCTION; SAMPLING; TIME;

AMIDOHYDROLASES; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BENZAMIDES; BORNANES; BRAIN; CARBAMATES; CARRAGEENAN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HINDLIMB; INDOMETHACIN; INFLAMMATION; MALE; MICE; MICE, INBRED C57BL; PENTOBARBITAL; PHENYLMETHYLSULFONYL FLUORIDE; PYRAZOLES; RECEPTORS, CANNABINOID; SPINAL CORD;

EID: 27144431754     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706348     Document Type: Article

References (62)

1. ATES, M., HAMZA, M., SEIDEL, K., KOTALLA, C.E., LEDENT, C. & GÜHRING, H. (2003). Intrathecally applied flurbiprofen produces an endocannabinoid-dependent antinociception in the rat formalin test. Eur. J. Neurosci., 17, 597-604.
2. BASSO, E., DURANTI, A., MOR, M., PIOMELLI, D., TONTINI, A., TARZIA, G. & TRALDI, P. (2004). Tandem mass spectrometric data-FAAH inhibitory activity relationships of some carbamic acid O-aryl esters. J. Mass Spectosc., 39, 1450-1455.
3. 2 receptors. Am. J. Physiol., 287, H595-H600.
4. BERGER, C., SCHMID, P.C., SCHABITZ, W.-R., WOLF, M., SCHWAB, S. & SCHMID, H.H.O. (2004). Massive accumulation of N-acylethanol-amines after stroke. Cell signalling in acute cerebral ischemia? J. Neurochem., 88, 1159-1167.
5. BEAULIEU, P., BISOGNO, T., PUNWAR, S., FARQUHAR-SMITH, P., AMBROSINO, G., DI MARZO, V. & RICE, A.S.C. (2001). Role of the endogenous cannabinoid system in the formalin test of persistent pain in the rat. Eur. J. Pharmacol., 396, 85-92.
6. BIFULCO, M., LAEZZA, C., VALENTI, M., LIGRESTI, A., PORTELLA, G. & DI MARZO, V. (2004). A new strategy to block tumor growth by inhibiting endocannabinoid inactivation. FASEB J., 18, 1606-1608.
7. BISHOP-BAILEY, D. & WARNER, T.D. (2003). PPARγ ligands induce prostaglandin production in vascular smooth muscle cells: indomethacin acts as a peroxisome proliferator-activated receptor-γ antagonist. FASEB J., 17, 1925-1927.
8. BISOGNO, T., LIGRESTI, A. & DI MARZO, V. (2005). The endocannabinoid signalling system: biochemical aspects. Pharmacol. Biochem. Behav., 81, 224-238.
9. BOLDRUP, L., WILSON, S.J., BARBIER, A.J. & FOWLER, C.J. (2004). A simple stopped assay for fatty acid amide hydrolase avoiding the use of a chloroform extraction phase. J. Biochem. Biophys. Methods, 60, 171-177.
10. 2 cannabinoid receptors are implicated in inflammatory pain. Pain, 96, 253-260.
11. COMPTON, D.R. & MARTIN, B.R. (1997). The effect of the enzyme inhibitor phenylmethylsulfonyl fluoride on the pharmacological effect of anandamide in the mouse model of cannabimimetic activity. J. Pharmacol. Exp. Ther., 283, 1138-1143.
12. CONTI, S., COSTA, B., COLLEONI, M., PAROLARO, D. & GIAGNONI, G. (2002). Antiinflammatory action of endocannabinoid palmitoylethanolamide and the synthetic cannabinoid nabilone in a model of acute inflammation in the rat. Br. J. Pharmacol., 135, 181-187.
13. COSTA, B., GIAGNONI, G., FRANKE, C., TROVATO, A.E. & COLLEONI, M. (2004). Vanilloid TRPV1 receptor mediates the antihyperalgesic effect of the nonpsychoactive cannabinoid, cannabidiol, in a rat model of acute inflammation. Br. J. Pharmacol., 143, 247-250.
14. CRAVATT, B.F., SAGHATELIAN, A., HAWKINS, E.G., CLEMENT, A.B., BRACEY, M.H. & LICHTMAN, A.H. (2004). Functional disassociation of the central and peripheral fatty acid amide signaling systems. Proc. Natl. Acad. Sci. U.S.A., 101, 10821-10826.
15. 1 receptors and tumor necrosis factor-α in the gut and systemic anti-inflammatory activity of SR 141716 (rimonabant) in rodents. Br. J. Pharmacol., 140, 115-122.
16. CROXFORD, J.L (2003). Therapeutic potential of cannabinoids in CNS disease. CNS Drugs, 17, 179-202.
17. CUZZOCREA, S., PISANO, B., DUGO, L., IANARO, A., MAFFIA, P., PATEL, N.S.A., DI PAOLA, R., IALENTI, A., GENOVESE, T., CHATTERJEE, P.K., DI ROSA, M., CAPUTI, A.P. & THIEMERMANN, C. (2004). Rosiglitazone, a ligand of the peroxisome proliferator-activated receptor-γ, reduces acute inflammation. Eur. J. Pharmacol., 483, 79-93.
18. DAHER, J.B. & TONUSSI, C.R. (2003). A spinal mechanism for the peripheral anti-inflammatory action of indomethacin. Brain Res., 962, 207-212.
19. DEUTSCH, D.G. & CHIN, S.A. (1993). Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol., 46, 791-796.
20. DEVANE, W.A., DYSARZ III, F.A., JOHNSON, M.R., MELVIN, L.S. & HOWLETT, A.C. (1988). Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 34, 605-613.
21. DI MARZO, V., BISOGNO, T., SUGIURA, T., MELCK, D. & DE PETROCELLIS, L. (1998). The novel endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and basophil-like cells: connections with anandamide. Biochem. J., 331, 15-19.
22. DI MARZO, V., BREIVOGEL, C., BISOGNO, T., MELCK, D., PATRICK, G., TAO, Q., SZALLASI, A., RAZDAN, R.K. & MARTIN, B.R. (2000). Neurobehavioral activity in mice of N-vanillyl-arachidonylamide. Eur. J. Pharmacol., 406, 363-374.
23. FEGLEY, D., GAETANI, S., DURANTI, A., TONTINI, A., MOR, M., TARZIA, G. & PIOMELLI, D. (2005). Characterization of the fatty-acid amide hydrolase inhibitor URB597: effects on anandamide and oleoylethanolamide deactivation. J. Pharmacol. Exp. Ther., 313, 352-358.
24. FORD, W.R., HONAN, S.A., WHITE, R. & HILEY, C.R. (2002). Evidence of a novel site mediating anandamide-induced negative inotropic and coronary vasodilatator responses in rat isolated hearts. Br. J. Pharmacol., 135, 1191-1198.
25. FOWLER, C.J. (2004). Metabolism of the endocannabinoids anandamide and 2-arachidonoyl glycerol, a review, with emphasis on the pharmacology of fatty acid amide hydrolase, a possible target for the treatment of neurodegenerative diseases and pain. Curr. Med. Chem. Central Nerv System Agents, 4, 161-174.
26. FOWLER, C.J., HOLT, S. & TIGER, G. (2003). Acidic non-steroidal anti-inflammatory drugs inhibit rat brain fatty acid amide hydrolase in a pH-dependent manner. J. Enzyme Inhibition Med. Chem., 18, 55-58.
27. GOPARAJU, S.K., UEDA, N., YAMAGUCHI, H. & YAMAMOTO, S. (1998). Anandamide amidohydrolase reacting with 2-arachidonoylglycerol, another cannabinoid receptor ligand. FEBS Lett., 422, 69-73.
28. GUBELLINI, P., PICCONI, B., BARI, M., BATTISTA, N., CALABRESI, P., CENTONZE, D., BERNARDI, G., FINAZZI-AGRÒ, A. & MACCARRONE, M. (2002). Experimental parkinsonism alters endocannabinoid degradation: implications for striatal glutamatergic transmission. J. Neurosci., 22, 6900-6907.
29. GÜHRING, H., HAMZA, M., SERGEJEVA, M., ATES, M., KOTALLA, C.E., LEDENT, C. & BRUNE, K. (2002). A role for endocannabinoids in indomethacin-induced spinal antinociception. Eur. J. Pharmacol., 454, 153-163.
30. HOLT, S., COSTA, B. & FOWLER, C.J. (2004a). FAAH inhibitors and indomethacin reduce carrageenan induced hind paw inflammation in the mouse - role of cannabinoid receptors. 2004 Symposium on the Cannabinoids, Burlington, Vermont. Int Cannabinoid Res Soc, 51.
31. HOLT, S., ROCKSÉN, D., BUCHT, A., PETERSEN, G., HANSEN, H.S., VALENTI, M., DI MARZO, V. & FOWLER, C.J. (2004b). Lipopolysaccharide-induced pulmonary inflammation is not accompanied by a release of anandamide into the lavage fluid or a down-regulation of the activity of fatty acid amide hydrolase. Life Sci., 76, 461-472.
32. HUANG, S.M., BISOGNO, T., PETROS, T.J., CHANG, S.Y., ZAVITSANOS, P.A., ZIPKIN, R.E., SIVAKUMAR, R., COOP, A., MAEDA, D.Y., DE PETROCELLIS, L., BURSTEIN, S., DI MARZO, V. & WALKER, J.M. (2001). Identification of a new class of molecules, the arachidonoyl amino acids, and characterization of one member that inhibits pain. J. Biol. Chem., 276, 42639-42644.
33. IKEDA, Y., UENO, A., NARABA, H. & OH-ISHI, S. (2001). Involvement of vanilloid receptor VR1 and prostanoids in the acid-induced writhing responses of mice. Life Sci., 69, 2911-2919.
34. 2 receptor. J. Pharmacol. Exp. Ther., 296, 420-425.
35. 1-receptor mediated regulation of gastrointestinal motility in mice in a model of intestinal inflammation. Br. J. Pharmacol., 134, 563-570.
36. JIN, K., XIE, S.H., PARMENTIER-BATTEUR, S., SUN, Y., MAO, X.O., CHILDS, J. & GREENBERG, D.A. (2004). Defective adult neurogenesis in CB1 cannabinoid receptor knockout mice. Mol. Pharmacol., 66, 204-208.
37. KATHURIA, S., GAETANI, S., FEGLEY, D., VALIÑO, F., DURANTI, A., TONTINI, A., MOR, M., TARZIA, G., LA RANA, G., CALIGNANO, A., GIUSTINO, A., TATTOLI, M., PALMERY, M., CUOMO, V. & PIOMELLI, D. (2003). Modulation of anxiety through blockade of anandamide hydrolysis. Nat. Med., 9, 76-81.
38. KEHL, L.J., HAMAMOTO, D.T., WACNIK, P.W., CROFT, D.L., NORSTED, B.D., WILCOX, G.L. & SIMONE, D.A. (2003). A cannabinoid agonist differentially attenuates deep tissue hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain, 103, 175-186.
39. LAMBERT, D.M. & FOWLER, C.J. (2005). The endocannabinoid system: drug targets, lead compounds, and potential therapeuticx applications. J. Med. Chem., 48, 5059-5087.
40. LEHMANN, J.M., LENHARD, J.M., OLIVER, B.B., RINGOLD, G.M. & KLIEWER, S.A. (1997). Peroxisome proliferator-activated receptors α and γ are activated by indomethacin and other non-steroidal antiinflammatory drugs. J. Biol. Chem., 272, 3406-3410.
41. LICHTMAN, A.H., LEUNG, D., SHELTON, C.C., SAGHATELIAN, A., HARDOUIN, C., BOGER, D.L. & CRAVATT, B.F. (2004a). Reversible inhibitors of fatty acid amide hydrolase that promote analgesia: Evidence for an unprecedented combination of potency and selectivity. J. Pharmacol. Exp. Ther., 311, 441-448.
42. LICHTMAN, A.H., SHELTON, C.C., ADVANI, T. & CRAVATT, B.F. (2004b). Mice lacking fatty acid amide hydrolase exhibit a cannabinoid receptor-mediated phenotypic hypoalgesia. Pain, 109, 319-327.
43. LO VERME, J., FU, J., ASTARITA, G., LA RANA, G., RUSSO, R., CALIGNANO, A. & PIOMELLI, D. (2005). The nuclear receptor PPAR-α mediates the antiinflammatory actions of palmitoylethanolamide. Mol. Pharmacol., 67, 15-19.
44. MASSA, F., MARSICANO, G., HERMANN, H., CANNICH, A., MONORY, K., CRAVATT, B.F., FERRI, G.-L., SIBAEV, A., STORR, M. & LUTZ, B. (2004). The endogenous cannabinoid system protects against colonic inflammation. J. Clin. Invest., 113, 1202-1209.
45. MOR, M., RIVARA, S., LODOLA, A., PLAZZI, P.V., TARZIA, G., DURANTI, A., TONTINI, A., PIERSANTI, G., KATHURIA, S. & PIOMELLI, D. (2004). Cyclohexylcarbamic acid 3′- or 4′-substituted biphenyl-3-yl esters as fatty acid amide hydrolase inhibitors: synthesis, quantitative structure-activity relationships, and molecular modelling studies. J. Med. Chem., 47, 4998-5008.
46. MUNRO, S., THOMAS, K.L. & ABU-SHAAR, M. (1993). Characterization of a peripheral receptor for cannabinoids. Nature., 365, 61-65.
47. NATARAJAN, V., SCHMID, P.C., REDDY, P.V. & SCHMID, H.H.O. (1984). Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J. Neurochem., 42, 1613-1619.
48. PARIA, B.C., DEUTSCH, D.D. & DEY, S.K. (1996). The uterus is a potential site for anandamide synthesis and hydrolysis: differential profiles of anandamide synthase and hydrolase activities in the mouse uterus during the periimplantation period. Mol. Reprod. Dev., 45, 183-192.
49. PERTWEE, R.G. (2002). Cannabinoids and multiple sclerosis. Pharmacol. Ther., 95, 165-174.
50. 2 blocks inflammation, hyperalgesia, and interleukin 6 production in vivo. J. Exp. Med., 184, 883-891.
51. 2 cannabinoid receptors. Anesthesiology, 99, 955-960.
52. QUISTAD, G.B., SPARKS, S.E., SEGALL, Y., NOMURA, D.K. & CASIDA, J.E. (2002). Selective inhibitors of fatty acid amide hydrolase relative to neuropathy target esterase and acetylcholinesterase: toxicological implications. Toxicol. Appl. Pharmacol., 179, 57-63.
53. RICE, A.S., FARQUHAR-SMITH, W.P. & NAGY, L. (2002). Endocannabinoids and pain: spinal and peripheral analgesia in inflammation and neuropathy. Prostagl. Leukot. Essent. Fatty Acids, 66, 243-256.
54. 2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 284, 644-650.
55. SIQUEIRA-JUNIOR, J.M., PETERS, R.R., DE BRUM-FERNANDES, A.J. & RIBEIRO-DO-VALLE, R.M. (2003). Effects of valeryl salicylate, a COX-1 inhibitor, on models of acute inflammation in mice. Pharmacol. Res., 48, 437-443.
56. 2 receptors in anaesthetised rats. Neuropharmacology, 45, 404-411.
57. TAYLOR, B.K., DADIA, N., YANG, C.B., KRISHNAN, S. & BADR, M. (2002). Peroxisome proliferator-activated receptor agonists inhibit inflammatory edema and hyperalgesia. Inflammation, 26, 121-127.
58. WALLACE, J.L., BAK, A., MCKNIGHT, W., ASFAHA, S., SHARKEY, K.A. & MACNAUGHTON, W.K. (1998). Cyclooxygenase 1 contributes to inflammatory responses in rats and mice: implications for gastrointestinal toxicity. Gasteroenterology, 115, 101-109.
59. WANG, Z.Q., PORRECA, F., CUZZOCREA, S., GALEN, K., LIGHTFOOT, R., MASINI, E., MUSCOLI, C., MOLLACE, V., NDENGELE, M., ISCHIROPOULOS, H. & SALVEMINI, D. (2004). A newly identified role for superoxide in inflammatory pain. J. Pharmacol. Exp. Ther., 309, 869-878.
60. 1 receptor mediated mechanism. Proc. Br. Pharm. Soc., http://www.pA2online.org/Vol2Issue4abst049P.html.
61. 2 ethanolamide from anandamide by cyclooxygenase-2. J. Biol. Chem., 272, 21181-21186.
62. ZYGMUNT, P.M., PETERSSON, J., ANDERSSON, D.A., CHUANG, H., SØRGÅRD, M., DI MARZO, V., JULIUS, D. & HÖGESTÄTT, E.D. (1999). Vanilloid receptors on sensory nerves mediate the vasodilator action of anandamide. Nature, 400, 452-457.